N@N

Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers

The article from MSN discusses why Beam Therapeutics (BEAM) is considered the worst ARK stock to buy according to short sellers. Beam Therapeutics, a company focused on precision genetic medicine through its base editing technology, has seen significant interest from ARK Investment Management, with ARK owning about 10% of the company. However, short interest in Beam has surged, with 20.5% of its float being sold short, making it the most shorted stock in ARK's portfolio. This skepticism stems from concerns over the company's high cash burn rate, the long timeline for bringing its therapies to market, and the competitive landscape in gene editing. Despite these concerns, ARK remains optimistic about Beam's potential, particularly with its lead candidate, BEAM-101, aimed at treating sickle cell disease. The article highlights the dichotomy between ARK's long-term investment strategy and the immediate financial pressures and market skepticism reflected by short sellers.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/technology/tech-companies/why-beam-therapeutics-beam-is-the-worst-ark-stock-to-buy-according-to-short-sellers/ar-AA1vGeSE ]